GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Cash Flow from Financing

MAIA (MAIA Biotechnology) Cash Flow from Financing : $18.36 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2024, MAIA Biotechnology received $0.66 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.03 Mil on other financial activities. In all, MAIA Biotechnology earned $0.63 Mil on financial activities for the three months ended in Sep. 2024.


MAIA Biotechnology Cash Flow from Financing Historical Data

The historical data trend for MAIA Biotechnology's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Cash Flow from Financing Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
0.80 14.03 12.48 9.27

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 5.03 4.72 7.99 0.63

MAIA Biotechnology Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

MAIA Biotechnology's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

MAIA Biotechnology's Cash from Financing for the quarter that ended in Sep. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MAIA Biotechnology  (AMEX:MAIA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

MAIA Biotechnology's issuance of stock for the three months ended in Sep. 2024 was $0.66 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

MAIA Biotechnology's repurchase of stock for the three months ended in Sep. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

MAIA Biotechnology's net issuance of debt for the three months ended in Sep. 2024 was $0.00 Mil. MAIA Biotechnology received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

MAIA Biotechnology's net issuance of preferred for the three months ended in Sep. 2024 was $0.00 Mil. MAIA Biotechnology paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

MAIA Biotechnology's cash flow for dividends for the three months ended in Sep. 2024 was $0.00 Mil. MAIA Biotechnology received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

MAIA Biotechnology's other financing for the three months ended in Sep. 2024 was $-0.03 Mil. MAIA Biotechnology spent $0.03 Mil on other financial activities.


MAIA Biotechnology Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606